These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1843369)

  • 1. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard and method independent units for heparin anticoagulant activities.
    Hemker HC; Béguin S
    Thromb Haemost; 1993 Nov; 70(5):724-8. PubMed ID: 8128425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assays and reference materials for current and future applications of heparins.
    Mulloy B; Hogwood J; Gray E
    Biologicals; 2010 Jul; 38(4):459-66. PubMed ID: 20338781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of unfractionated heparin: comparison of materials from the last 50 years.
    Mulloy B; Gray E; Barrowcliffe TW
    Thromb Haemost; 2000 Dec; 84(6):1052-6. PubMed ID: 11154113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity.
    Palm M; Mattsson C; Svahn CM; Weber M
    Thromb Haemost; 1990 Aug; 64(1):127-32. PubMed ID: 2177229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
    Takahashi HK; Nader HB; Dietrich CP
    Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity.
    Lippman MM; Mathews MB
    Fed Proc; 1977 Jan; 36(1):55-9. PubMed ID: 830557
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparins from porcine and bovine intestinal mucosa: Are they similar drugs?
    Aquino RS; Pereira MS; Vairo BC; Cinelli LP; Santos GR; Fonseca RJ; Mourão PA
    Thromb Haemost; 2010 May; 103(5):1005-15. PubMed ID: 20216993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of modified heparins on coagulation: in vitro and in vivo studies.
    Stemberger AW; Riedl A; Haas S; Breddin HK; Walenga JM; Blümel G
    Semin Thromb Hemost; 1991; 17 Suppl 1():80-4. PubMed ID: 1648792
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular weight determination of commercial heparin sodium USP and its sterile solutions.
    Rodriguez HJ; Vanderwielen AJ
    J Pharm Sci; 1979 May; 68(5):588-91. PubMed ID: 571022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.
    Bjornsson TD; Schneider DE; Hecht AR
    J Pharmacol Exp Ther; 1988 Jun; 245(3):804-8. PubMed ID: 3164387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.